CardiologyOnline.net

Cardiology Xagena

Researchers at University of Manchester ( Manchester, UK = previously reported Omega-3 polyunsaturated fatty acids ( n-3PUFAs ) supplementation does not reduce atrial fibrillation following coronary a ...


A study has evaluated the prospective association between circulating 25-hydroxyvitamin D [ 25(OH)D ] and atrial fibrillation risk. 12 303 participants from the Atherosclerosis Risk in Communities ...


Various ablation strategies of persistent atrial fibrillation ( PersAF ) have had disappointing outcomes, despite concerted clinical and research efforts, which could reflect progressive atrial fibril ...


While bleeding is a well-known complication of Warfarin ( Coumadin ) use and is thought to be a contributory cause of treatment discontinuation, studies quantifying this association are limited. The ...


Researchers performed a prospective, randomized clinical study ( PRESAGE ) to assess whether prophylactic treatment with Metoprolol or Losartan, initiated soon after lung cancer surgery in patients wi ...


Plasma norepinephrine ( NE ) level can be a guide to mortality in patients with heart failure. A study aimed to evaluate the significance of plasma norepinephrine level compared with plasma natriureti ...


A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart failure ( HF ) with and without diabetes in the Swedish Heart Failure Regist ...


The Fontan circulation is associated with an increased risk of thromboembolic events ( TEs ). As many as 25% of these thrombotic events result in fatality. More subtle adverse effects on the pulmonary ...


Atrial fibrillation is often asymptomatic, but outcomes require further characterization. The study objective was to investigate the clinical presentation, management, and outcomes in asymptomatic and ...


Currently available antiarrhythmic agents for the treatment of atrial fibrillation have important limitations, leaving an unmet need for safe and effective therapy. Ranolazine is an approved antiang ...


The purpose of the study was to describe the associated baseline features of atrial fibrillation patients with heart failure ( HF ) with reduced and preserved ejection fraction ( HFrEF and HFpEF ). ...


Research presented at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers ( Venneri L et al ) from t ...


Activation of the endothelin system has been demonstrated in both plasma and lung tissue of PAH ( pulmonary arterial hypertension ) patients. Although it is unclear if the increases in endothelin-1 pl ...


When considering antiplatelet therapy for acute coronary syndrome ( ACS ), it is essential to balance benefits ( less thrombotic / ischaemic events ) versus bleeding risks related to intense platelet ...


Coronary stent thrombosis is a devastating complication after percutaneous coronary intervention ( PCI ). The mechanisms underlying stent thrombosis are multifactorial. Whether the coagulation syste ...


In the Apixaban for Prevention of Acute Ischemic Events ( APPRAISE-2 ) trial, the use of Apixaban ( Eliquis ), when compared with placebo, in high-risk patients with a recent acute coronary syndrome ( ...


In heart failure patients with diabetes mellitus and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist ( MRA ) called Finerenone was no more effective than the curr ...


The immunosuppressant drug Cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention ( PCI ) for the more severe form of heart attack ...


The American Heart Association Cardiovascular Health ( CVH ) score is inversely associated with cardiovascular disease, but its relations to cardiac remodeling traits and heart failure ( HF ) incidenc ...


Ticagrelor ( Brilinta, Brilique ) administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention ( PCI ), according to findings from the ATLANTIC-H24 ...


A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Ticagrelor ( Brilinta, Brilique ) in reducing atherothrombotic events in post-myocardial infarction patients, based on the time fro ...


The ESC Guidelines for the management of infective endocarditis are published in European Heart Journal, For the first time, the guidelines recommend that an endocarditis team operating in a referenc ...


The landmark Dual Antiplatelet Therapy ( DAPT ) trial revealed an impressive reduction of stent thrombosis and myocardial infarction after prolonged 30-month DAPT compared to the conventional 12-month ...


Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic events is clinically perce ...


Myocardial infarction patients without heart failure derive no benefit from the addition of mineralocorticoid receptor antagonists ( MRA; antimineralocorticoids ), to standard therapy, results of the ...


Researchers from the PATHWAY 3 study have found that the combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full ...


The BENEFIT trial has shown that a 40 to 80 day treatment with the antiparasitic medication Benznidazole ( Rochagan, Radanil ) significantly has reduced parasite activity, but not progression of seri ...


The SERVE-HF trial has shown that adaptive servo-ventilation ( ASV ) therapy increases mortality and should not be used to treat central sleep apnoea in heart failure patients with reduced ejection f ...


The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases are published in European Heart Journal. Previous ESC Guidelines on this topic were published in 2004. The pericardiu ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and the European Respiratory Journal. The document was written joint ...


The FDA ( Food and Drug Administration ) is alerting health care providers, patients, and caregivers about serious adverse events associated with implantable left ventricular assist devices ( LVADs ). ...


ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI ) in patients with acute coronary syndromes ( ACS ). The ...


Data from the expansion phase of COSMIC-HF ( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure ), a phase 2 trial evaluating Omecamtiv mecarbil in patients with chroni ...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with Entresto ( Sacubitril / Valsartan ) tablets were readm ...


The results of a sub-analysis of the PEGASUS-TIMI 54 study, which evaluated reasons and rates for discontinuation of Ticagrelor ( Brilinta, Brilique ) in patients with a history of myocardial infarcti ...


Beta-blocker therapy after acute myocardial infarction ( MI ) improves survival. Beta-blocker doses used in clinical practice are often substantially lower than those used in the randomized trials est ...


Several studies have shown that Exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation myocardial infarction ( STEMI ). The ...


There is a paucity of data on the impact of complete revascularisation ( CR ) following percutaneous coronary intervention ( PCI ) among patients with diabetes mellitus and with multivessel coronary d ...


Pericarditis is the most common form of pericardial disease and a relatively common cause of chest pain. The objective of a study was to summarize published evidence on the causes, diagnosis, therapy, ...


More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adul ...


Myocardial infarction patients treated with a substantially lower dosage of beta-blockers than used in earlier clinical trials showing their effectiveness survived at the same rate, or even better, t ...


A new analysis of the TECOS ( Trial Evaluating Cardiovascular Outcomes with Sitagliptin ) trial has shown that patients with type-2 diabetes and cardiovascular disease can safely take the antihypergl ...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared with Enalapril in patients with chroni ...


A study has investigated the prevalence and potential incremental prognostic value of combined free light chains ( cFLCs ) in patients recently hospitalized with decompensated heart failure ( HF ). ...


A study sought to hypothesize that elevated B-type natriuretic peptide ( BNP ) could act as an endogenous neprilysin inhibitor. A hallmark of acute decompensated heart failure ( ADHF ) is the overp ...


A study sought to examine the prognostic value of the soluble form of neprilysin ( sNEP ) in acute heart failure ( AHF ) and sNEP kinetics during hospital admission. sNEP was recently identified in ...


Fine particulate matter air pollution ( PM2.5 ) and extreme temperatures have both been associated with alterations in blood pressure ( BP ). However, few studies have evaluated their joint haemodynam ...


Postoperative atrial fibrillation ( POAF ) is a common complication after cardiac surgery and predicts increased morbidity and mortality. Identification of patients at high risk of postoperative atri ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati